

## Singapore 2021 Equity Strategy

Equities in a sweet spot

Paul Chew
Head Of Research
Phillip Securities Research Pte Ltd
9 January 2021



#### Disclaimer

The information provided in this seminar is solely for educational purposes and should not be considered as financial advice. The views, statements and opinions expressed in this seminar are solely the views, statements and opinions of the presenter made in his/her personal capacity and do not represent the views, statements or opinions of nor are they made on behalf of Phillip Securities Pte Ltd (PSPL).

The information contained in this presentation has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this presentation are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this presentation is subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

This presentation is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person.

You should seek advice from a financial adviser regarding the suitability of the investment products mentioned, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

## Agenda

- ✓ Review of 2020 performance
- ✓ Sector views

✓ Economic conditions

✓ All our BUYs

✓ Macro drivers

✓ Conclusion


√ Technicals



Review of 2020 Performance

## **Everything But Us Rally in 2020**


STI Vs Other Asset Classes (USD terms)



Source: PSR, Bloomberg \*Bonds ETF is iShares Investment Grade Corporate Bonds (LQD), Gold ETF is SPDR Gold Shares (GLD)




#### STI weakness was from banks, telco, property



Source: PSR, Bloomberg




## 30 stocks, only 9 has gains in 2020





#### Sector performance in 2020 was very narrow




Source: PSR, Bloomberg





#### Worst ever (intentional) GDP decline is over



2021 forecast is largest GDP reversal since 2010

STI performance after deep GDP contraction:

1986 +43.7%

1999 +78.0%

2002 -17.4%


2010 +10.1%\*

Source: PSR CEIC, MTI, \* 2009 GDP +0.1



## V shape for global manufacturing






US manufacturing has been exceptionally strong

Source: PSR CEIC, Markit



#### **Activity not fully returned to Singapore**






Office workers not back but retail creeping up

Source: PSR, https://www.google.com/covid19/mobility/ (27Sep20)



### Stimulus saved the U.S. economy

US: Personal Disposable Income (US\$bn)




- Income for US
  workers and
  small businesses
  rose from \$3t
  stimulus
- \$900bn
  -US\$600 per adult
  / US\$600 per
  dependent
  -US\$300/week
  unemployment
  subsidy, etc.

Source: PSR, BEA, CEIC



### China is re-leveraging

CH: Net disbursement in loans (12 months rolling RMB bn)



- Aggressive monetary stimulus since Jan20
- Positive for commodity prices with a lag
- Fixed asset investments rebounding strongly

Source: PSR, BEA, CEIC





#### How was our 2020 forecast?

#### 2020 Themes

Trade ceasefire

1/2 Pass

Domestic recovery

pass

**Buoyant electronics** 

1/2 Pass

Binary political events

Less momentum in rates

2021 Themes

Boom in global growth

Vaccines to bend infection curve

Interest rates remain conducive

Prolonged growth in tourism

...... MOE: PSLE markings focus on learning not a race to outdo others



## Theme 1: Vaccination available for 5.25bn people

| Company               | Country     | Туре        | Name        | Doses   | Efficacy | Approval  | Doses     |
|-----------------------|-------------|-------------|-------------|---------|----------|-----------|-----------|
|                       |             |             |             | / Weeks |          |           | 2021 (mn) |
| 1) Pfizer/BioNTech    | USA/Germany | mRNA        | Comirnaty   | 2 + 3   | 95.0%    | 11-Dec-20 | 1,300     |
| 2) Moderna            | USA         | mRNA        | mRNA-1273   | 2 + 4   | 94.5%    | 18-Dec-20 | 500       |
| 3) Sinopharm-Beijing  | China       | Inactivated | BBIBP-CorV  | 2 + 3   | 79.0%    | 30-Dec-20 | 1,000     |
| Sinopharm-Wuhan       | China       | Inactivated | -           | -       | -        | -         | -         |
| 4) AstraZeneca/Oxford | UK/Sweden   | Adenovirus  | AZD1222     | 2 + 4   | 90.0%    | 30-Dec-20 | 2,000     |
| 5) Sinovac Biotech    | China       | Inactivated | CoronaVac   | 2 + 2   | > 50%    | -         | 600       |
| 6) CanSino Biologics  | China       | Adenovirus  | Convidecia  | 1       | -        | -         | 200       |
| 7) Gamaleya           | Russia      | Adenovirus  | Sputnik V   | 2 + 3   | 91.4%    | -         | 1,000     |
| 8) Novavax            | USA         | Protein     | NVX-CoV2373 | 2 + 3   | -        | -         | 1,400     |
| 9) J&J/Beth           | US/Israel   | Adenovirus  | Ad26.COV2.S | 1       | -        | -         | 1,000     |
| 10) CureVac           | Germany     | mRNA        | CVnCoV      | 2 + 4   | -        | -         | 300       |
|                       |             |             |             |         |          |           | 9,300     |


Source: PSR, NY Times

Approved / Limited Use / Phase 3



#### Global cases still elevated

COVID-19 New Daily Cases (7DMA)




Global infection rates tapering down but still double the numbers 3 months ago

Source: PSR, CEIC, WHO



### Asia undergoing a major 3<sup>rd</sup> wave too






# Record cases in Japan and Malaysia

Source: CEIC, PSR, WHO



#### Unlike many others, Singapore is easing




Recent spike at year-end

Source: PSR, MOH



### Theme 2: The hunt for yield remains

#### Negative Yielding Debt and Bitcoin




- Record US\$17.7t
   of negative
   yielding debt
- Like "trading tulips", reflects loss of central bank trust and negative interest rate

Source: PSR, Bloomberg



#### Please don't cross 2% until ..... End 2023






- Goal 1: Moderately >2% inflation for some time (2.25-2.5%)
- Goal 2: Helping workers - maximum employment (4%)
- Fed still in QE mode until "substantial further progress" in goal

Source: CEIC, Bureau of Economic Analysis, PSR



## Theme 3: No bridge give money fiscal stimulus




- Handouts more effective than tax cuts or government guarantees
- Government
  guarantees another
  way for off balance
  sheet financing

Source: PSR, CEIC




### Theme 4: Equities still the better asset



- PE record high after 40% cut in earnings
- PE based on pre-COVID earnings is 11.5x
- 4% dividend yield

Source: PSR, Bloomberg





**Technicals** 

## Straits Time Index: Monthly Chart. 3,000 is poised to break

- We are still in a complex corrective phase for the past 12 years since 2009.
- STI is poised to clear 3,000 as the monthly candle is approaching the immediate resistance fiercely. However, the next resistance zone at 3,250 remain a strong resistance zone
- Only by clearing 3,44.89 then STI will confirms its impulse 3<sup>rd</sup> wave move.



Source: Bloomberg, PSR



## Straits Time Index: Corrective symmetrical triangle

- Another theory is that STI is forming an ongoing corrective 5-wave triangle. Currently only wave ((A)), ((B)), ((C)) is completed.
- Should 3,500 level breaks with a strong upside, then the probability of wave ((D)) invalidation will increase along with the new impulse wave (III).



## Straits Time Index: Daily Chart. Breakaway gap signal a new bullish momentum


- As STI is slowly approaching the resistance zone near 78.6% Fibonacci retracement, there may be some short term correction ahead but we believe that STI will reach C(ii) at 3,231 level within the first quarter of 2021.
- The breakaway gap from the pennant on Thursday signify a strong bullish upside.





## Straits Time Index: Daily Chart. Ichimoku is showing "Sanyaku Kouten"


- Ichimoku display an extraordinary bullish signal other than the usual Sanyaku Kouten". The "kumo", which is the distance between Senkou-Span A and B is widening and this time round, both Senkou-Span A and B are moving upwards in tendem.
- Also, the pennant which is shown in the earlier chart is considered a strong bullish "P" wave.





## AEM Holdings – Primary 5th wave has yet to be completed

- So far from the history of the wave of AEM holdings, only wave (1) to (3) is completed and wave (4) is potentially complete unless prices rejects the resistance zone strongly and if it does, it can be a complex corrective flat or double/triple three sub-waves.
- Therefore, AEM has yet to complete the final last impulse/motive moves.








**Sector Views** 

### **Banking: Waiting game**

#### Average NIM (%) vs.Benchmark Rates (%)



| Average | 3M-SIBOR       | 3M-SOR         | NIM   |
|---------|----------------|----------------|-------|
| 4Q20    | 0.41% (-36bps) | 0.18% (-34bps) | -     |
| 9M20    | 0.77%          | 0.52%          | 1.63% |

#### 2020 Review

Bore brunt of economic fallout

- 150bps rate cut in March hurt margins
- Credit costs heightened
  - Loan quality at risk with stagnant economy
  - Pre-emptive provisioning
  - Dividend cap by MAS
- Weak loans growth

Capital market volatility benefited SGX

 SDAV and DDAV spiked on heightened market participation

Source: Companies, Bloomberg, PSR



#### **Banking: Waiting game**

|                             |                      | DBS           | OCBC          | UOB           |
|-----------------------------|----------------------|---------------|---------------|---------------|
| Credit cost guidance (bps)  |                      | 80 - 130      | 100 - 130     | 80 - 100      |
| Expected allowances (S\$mn) |                      | 3,000 - 5,000 | 2,700 - 3,500 | 2,200 - 2,800 |
|                             | RLAR reserves        | 404           | 876           | 114           |
| FY19                        | ECL stage 1 & 2 (GP) | 2,511         | 1,048         | 1,985         |
| (pre-COVID-19)              | ECL stage 3 (SP)     | 2,502         | 1,397         | 1,626         |
|                             | Total reserves       | 5,417         | 3,321         | 3,725         |
| Cumant                      | RLAR reserves        | -             | 874           | 379           |
|                             | ECL stage 1 & 2 (GP) | 4,017         | 1,863         | 2,712         |
|                             |                      | (+ 1,506)     | (+815)        | (+ 727)       |
| Current                     | ECL stage 3 (SP)     | 2,969         | 1,881         | 1,664         |
|                             | Total reserves       | 6,986         | 4,618         | 4,755         |
|                             | Total reserves       | (+ 1,304)     | (+ 1,063)     | (+ 709)       |
|                             | Compared to guidance | 31 - 52%      | 37 - 48%      | 37 - 47%      |

#### **2021 Outlook**

Waiting on re-rating catalysts

- Loan moratorium expiry to grant clarity on loan quality
  - > Tapering of credit costs
- Lift in dividend cap
- Possible loan uptick with economic recovery

Market participation to taper slightly

#### **Recommendation**

Remain NEUTRAL. Stock picks include:


- 1. SGX (SGX SP, ACCUMULATE, TP: S\$9.45)
- 2. UOB (UOB SP, NEUTRAL, TP: S\$21.10)

Source: Companies, PSR



#### **Healthcare: Pain subsides**

#### Healthcare Demand (3MMA YoY)



#### 2020 Review

Disruptions amidst COVID-19

- Aversion to hospital and clinic visits
- Travel restrictions hit medical tourism and supply chain alike
  - Demand hit from lack of foreign patients
  - Costs of transportation for medical supplies

Handful of winners emerged


- Medical PPE manufacturers
- COVID-19 test kits distributors

Source: CEIC, PSR



#### **Healthcare: Pain subsides**





|               | Trough (YoY) | Current (YoY) |
|---------------|--------------|---------------|
| Public Hosp.  | -13%         | -6%           |
| Private Hosp. | -30%         | -14%          |
| Specialist    | -45%         | +1%           |
| Dental        | -76%         | -15%          |

Source: CEIC. PSR

#### 2021 Outlook

Healthy recovery expected

- Pent-up demand for medical services
- Telemedicine gains traction
- Possible recovery of medical tourism
- Demand for medical PPE and test kits to normalise

#### **Recommendation**


Upgrade to ACCUMULATE. Stock picks include:

- 1. iX Biopharma (IXBIO SP, BUY, TP: S\$0.455)
- 2. UG Healthcare (UGHC SP, BUY, TP: S\$1.35)



#### **Utilities: Nascent recovery**

India Industrial Production Electricity Index




#### **2020 Review**

Nascent signs of recovery

- China has seen a faster pace of recovery vs. India
- India
  - Remained lackluster in the fourth quarter due to resurgence of COVID-19
  - Plant load factor improved to ~55% in December from 50%-52% in June
- China
  - Economic activity expanded in 4Q with output growth and retail sales growth
  - Plant load factor improved to ~68% in December from 55%-60% in June



### Utilities: Economic activity expected to improve in 2021



Source: Company, PSR

#### 2021 Outlook

- Economic activity expected to improve in 2021
- China outlook upgraded: GDP expected to expand to 8.0% in 2021 from 7.7% previously
- India growth expected to remain weak in 1H2021
- ➢ High COVID-19 cases (~20,000 average) presents challenges in the economic front
- Falling number of cases offers hopes of recovery by 2H2021


#### **Recommendation**

**Downgrade to NEUTRAL. Stock pick:** 

 Sembcorp Industries (SCI SP, Neutral, TP: S\$1.75)



### Marine: Prolonged downturn prompts action



#### **2020 Review**


Bore brunt of COVID-19


- Oil price turned negative for the first time in history in April 2020
- Oil price subsequently recovered but stayed weak
  - Weak economic activity due to worldwide lockdowns
  - Lack of a deal within OPEC
- Oil majors slashed CAPEX in anticipation of a prolonged downturn
  - More than 50 oil and gas firms filed for bankruptcy
  - Upstream capex cut by 22%

Source: Company, PSR



### Marine: Uncertain outlook prompts action





Source: Company, PSR

#### 2021 Outlook

Slight improvement in oil and gas sector activity in 4Q20

- Outlook for 2021 expected to remain weak
  - Oil price expected to average US\$49/barrel in 2021 according to EIA
  - Economic outlook expected to be affected by pace of economies opening up
- Oil majors capital expenditure expected to be about 11% lower vs. 2020

#### **Recommendation**


Maintain ACCUMULATE on potential divestment of O&M. Stock pick:

1. Keppel Corp (KEP SP, BUY, TP: S\$6.12)




## **Property market resilient despite Covid-19**

#### pts URA property price indices by region



Source: URA (rebased 1Q2009), CEIC, PSR


## Private Residential: Quarterly new and resale No. of units



Source: URA, CEIC, PSR




#### Private Residential: 26K units unsold, down 17% YoY 3Q20




# Uncompleted Launches/Take-ups 20,000 15,000 10.000 5,000 Launches —— Take-up Source: URA, PSR



### Prices mildly positive, expecting 9k units to be sold






- Private housing market indirect beneficiary of BTO construction delay and resale grants
- Demand from upgraders c.25k HDBs will achieve MOP
- Low interest rate and attractive launch units
- Low GLS 22% on the Confirmed List
- Strong household balance sheet pre-COVID – LTV fell from 53% to 49% over 2 years
- Possibly more property cooling measures



## REITs: On stable footing and seeking growth

#### **REITs outperformed STI and FTSE RE Index**




Source: Bloomberg, PSR

#### Dividend yield spread of 3.4% at -0.12 SD level






#### Recovery by subsector



|              | Healthcare | Hospitality | Retail | Commercial | Industrial | Diversified |
|--------------|------------|-------------|--------|------------|------------|-------------|
| Change YTD   | -4.9%      | -26.6%      | -18.5% | -19.2%     | 6.2%       | -16.7%      |
| Max Drawdown | -27.8%     | -54.8%      | -37.4% | -41.5%     | -29.9%     | -39.3%      |



#### Retail – Lifted by easing of containment measures




- Lifted by further reopening and relaxation of containment measures
  - Suburban Increase in daytime population from permanent hybrid work arrangements
- Dominant, well located and managed malls will be prioritised amidst retail consolidation
- Landlords have offered leases with higher variable rent component for some tenants
- Retail Sales Index (excl. MV) -3.1% YoY in Nov20
- Declining rents landlords prioritise occupancy over rents
- Digital transformation to increase customer and tenant stickiness

YoY - Central: -10.2%, Suburban: -4.4%, Occupancy: -2.1ppts



### Office - Structural decline mitigated by tight supply




- Structural decline weak demand & challenging leasing
- Permanent hybrid work arrangements; setting in motion more aggressive rightsizing in mid-term
  - Tenants giving back 10-30% of space
- More demand from coworking operators as flexible space could be used an interim strategy
- Supply may be taken offline for redevelopment
- CBD Incentive Scheme (Redevelopment 2021/22)
  - AXA Tower (700K sq ft)
  - Fuji Xerox Tower (354K sq ft)
  - Central Mall (131K sq ft)
- Singapore remains an attractive location for regional headquarters

**3Q20 YoY - Central: -8.3%, Fringe: -6.9%, Occupancy: -1.4ppts** 



### Industrial - Backbone of the economy




- Data centres, hi-spec and business parks remain favourable, supported by
  - Technology, biomedical and precision engineering sectors
  - Limited new supply
- Warehouses may benefit from higher demand from logistics players
- Factories more challenged, recovering global demand and considerable supply

3Q20 YoY - Rental Index: -1.6%, Occupancy: +0.3ppts



## Hospitality - Vaccine courage to lift sector




Nov YoY - RevPAR: -59.5%, ADR: -33.2%, Occupancy: -35.1ppts

- Future business travel will be more targeted and less frequent – virtual meetings may replace some trips
- MICE demand will remain strong business engagement and networking difficult to replicate virtually
- COVID-19 set new historical lows Lower minimum rent in future lease negotiations
- Leaner cost and operating structures through adoption of digital technology
- Pent –up demand for leisure travel
- Countries with sizeable domestic travel markets will be the first to recover – China, France, Japan, US, UK, Australia, Spain and Brazil



### Consumer: Groceries still rising 22x historical trend

#### SG: Supermarket Vs Industry Retail Sales (3MMA YoY)




- Nov20, overall retail improving with -3% YoY + supermarket +22% YoY
- Income is down and employment at 3.6mn, 7-year low

Source: CEIC. PSR. DOS



### Construction: Will rebound and support economy

SG: Construction demand & work (S\$mn - T12M)




Worker shortage and separated will slow activity

Source: CEIC, PSR, BCA



#### **Defence: stable growth**




- This year revenue hurt by commercial aircraft business
- STE pays a yield of 4%

Source: PSR, Company, MoF



## **Telecommunications: Optus hurt by NBN**






- Optus: Broadband margin drop and stubborn cost
- · Associates: Bharti recovery
- 5G: every migration new revenue; speed, connectivity and capacity is a commodity
   + need new applications
- +ve: valuations and NBN cost but contend with lower government subsidies
- Rating: NEUTRAL




#### Telecommunications: 20% mobile revenue is hurt



- Since 2017, prices on freefall
- Malaysia and China are key countries

PhillipCapital
Your Partner In Finance


#### **Aviation: Life or Livelihood**



- A very gradual rebound
- Competition not abated and more leveraged than pre-COVID levels
- 10Y price to book range is 0.7x 1.7x with avg.
  1.1
- Currently 0.84x on S\$5.14 but 1.2x on adjusted S\$3.57, unless S\$3.5vb MCBs are repaid

PhillipCapital
Your Partner In Finance

#### Transportation: Gradual improvement as enter Phase 3




More activity but WFH and tourism will keep travel below par

Source: CEIC, PSR,



#### Transportation: Container turned rocketship






- Record levels due to surge in imports and delays due to pandemic
- Next wave possible is ship orders
- Shortage of containers

PhillipCapital
Your Partner In Finance

56

## Technology (Hardware): Multi year growth

#### Growth of Electromotive (xEV) vehicles (m)



- Semiconductor sales up 6% this year
- Cloud capex rising due to WFH economy
- Electro-mobility for emission standards and automated driving L2/L2+
- Chip content +44% for mild hybrid or +111% for EV
- 5G adoption / memory use surge from AI, analytics, storage, etc

Source: PSR, Infineon \*FHEV - Full hybrid, PHEV - Plug-in; BEV - Battery EV





## Phillip Absolute 10 Model Portfolio

| Company                         | 1M        | 3M    | YTD    | Rating | Target Px (S\$ | ) Share Px (S\$) | Upside | Mkt Cap (US\$m) | Dvd. Yield |
|---------------------------------|-----------|-------|--------|--------|----------------|------------------|--------|-----------------|------------|
| <u>Yield</u>                    |           |       |        |        |                |                  |        |                 |            |
| Ascott REIT (New)               | 3.8%      | 21.3% | -18.8% | Buy    | 1.15           | 1.080            | 6%     | 2,542           | 3.7%       |
| Asian PayTV                     | -0.8%     | -4.0% | -29.6% | Buy    | 0.15           | 0.119            | 26%    | 163             | 8.8%       |
| Manulife US REIT                | 0.0%      | 0.7%  | -25.5% | Buy    | 0.92           | 0.745            | 23%    | 1,179           | 8.6%       |
|                                 |           |       |        |        |                |                  |        |                 |            |
| <b>Dividend / Earnings Grow</b> | <u>th</u> |       |        |        |                |                  |        |                 |            |
| Frasers Centrepoint Tr          | 6.0%      | 3.2%  | -12.2% | Buy    | 2.79           | 2.46             | 13%    | 3,163           | 5.4%       |
| PropNex                         | 13.0%     | 31.1% | 51.5%  | Buy    | 0.85           | 0.78             | 9%     | 219             | 5.1%       |
| Thai Beverage                   | -0.7%     | 21.5% | -17.4% | Buy    | 0.86           | 0.74             | 17%    | 13,980          | 3.2%       |
|                                 |           |       |        |        |                |                  |        |                 |            |
| Re-rating Plays                 |           |       |        |        |                |                  |        |                 |            |
| CapitaLand                      | 4.8%      | 21.0% | -12.5% | Buy    | 3.82           | 3.28             | 16%    | 12,899          | 3.7%       |
| ComfortDelgro                   | 1.2%      | 18.4% | -29.8% | Buy    | 1.83           | 1.67             | 10%    | 2,740           | 3.9%       |
| Keppel Corp. (New)              | 6.1%      | 20.9% | -20.5% | Buy    | 6.12           | 5.38             | 14%    | 7,405           | 1.7%       |
| Yoma                            | 3.6%      | 1.8%  | -17.1% | Buy    | 0.46           | 0.29             | 59%    | 491             | 0.0%       |
| Average                         | 3.70%     | 12.7% | -12.6% |        |                |                  | 21%    | 42,239          | 4.5%       |

|         | Absolute  | STI    |  |
|---------|-----------|--------|--|
|         | 10        |        |  |
| Jan20   | -0.5%     | -2.1%  |  |
| Feb20   | -1.6%     | -4.5%  |  |
| Mar20   | -16.4%    | -17.6% |  |
| Apr20   | 10.1%     | 5.8%   |  |
| May20   | 1.0%      | -4.3%  |  |
| Jun20   | 1.8%      | 3.2%   |  |
| Jul20   | -2.4%     | -2.3%  |  |
| Aug20   | 3.2%      | 0.1%   |  |
| Sep20   | -2.1%     | -2.6%  |  |
| Oct20   | -4.5%     | -1.7%  |  |
| Nov20   | 11.0%     | 15.7%  |  |
| Dec20   | 3.2%      | 1.4%   |  |
| YTD     | -0.1%     | -11.8% |  |
| Out/(Un | der)perf. | 11.6%  |  |

... we outperformed but it does not pay the bills


# Removed - NetLink and SGX.

Source: Bloomberg, PSR, As at 31Dec20, Performance is for illustration only and excludes brokerage, dividends and monthly rebalancing cost.



### Asian PayTV: Stable cash-flow and 5G






- Monopoly cable TV provider in four counties in Taiwan
- Subscribers stable with growth of broadband
- 2 reason to be positive
- a. Sustainable dividends: \$50mn FCF vs S\$18mn dividend
- b. Optionality of high margin 5G
   back-haul service for mobile
   operators
- Rating: BUY; Target price \$\$0.15; Distribution yield: 8.8%



## ComfortDelgro: Recovering and taking share

SBS Transit: Monthly rail passengers




- Stock 30% down from pre-Covid, generated \$383mn operating cash-flow, back to net cash \$\$115mn and our proxy to reopening and recovery
- Rail passengers recovering
- Taxi and bus market share of 60%; Attractive rental model
- Grab still a formidable competitor and fleet share is likely rising
- Rating: BUY; TP: S\$1.83

Source: LTA, PSR



#### PropNex: 2021 can surprise

SG: Quarterly New Sales (Ex-EC)



- Market share of around 50% in private and HDB home sales
- Volumes this year down ~10% till Nov20; but Dec20 robust ... UOL;s Clavon sold 442 units or 70% on 1st day
- ROE unleveraged 28% on fixed assets of S\$4mn and net cash S\$93mn
- Sustainable yield of 5% (S\$15mn p.a. vs S\$20-30mn operating cashflow)
- Rating: BUY; TP: S\$0.85


Source: URA PSR



Phillip Securities accepts no liability whatsoever with respect to the use of this document or its contents.

## Thai Beverage: Dominate the spirit





- 90% market share of spirits market in Thailand; spirits account for 86% of PATMI; FY20 spirits volume up 0.2%
- Results resilient to due aggressive cost cutting; e.g. S\$180mn in marketing and distribution
- Valuations attractive at 14x PE on vs 18x historical
- Generated FCF of THB32bn or S\$1.4bn in FY9/20
- Rating: BUY; TP: S\$0.86

Source: CEIC, PSR



#### **UG Healthcare: Fundamentals still healthy**




- Demand growing even before COVID-19
- 60% rise in capacity over 2 years
- Penetration rate in Brazil 24 and China 10 per capita vs U.S. 150
- Post vaccine: non-traditional user of gloves + increased spending and awareness + vaccinations and PPE continue
- 14x PE FY22
- Rating: BUY; TP: S\$1.35

Source: PSR, Malaysian Rubber Glove Manufacturers Association

#### Yoma Strategic: Solidly anchored by property and Wave Money

Yoma is a leading conglomerate in Myanmar, with 4 key business lines: property (FY20: 39%), F&B (30%), motors (23%) and financial services (7%).




- Large property land bank equivalent to 10-15 years of sale - Yoma Central, Pun Hlaing Estate, Star City
- Financial services continue to grow as Wave Money doubled its net profit YoY in FY20.
- Unrecognised revenue from Yoma Land and Yoma Motors to contribute 33% to FY21e topline.
- Attractive valuations, affirmed by Ayala's investment at S\$0.45/share.

Rating: BUY; TP: S\$0.46



#### First Sponsor Group: Property development, the growth driver

FSG is a property developer (FY19 revenue: 50%), owner (22.5%) and financier (27.5%).



From 2015-2019, PF loan book grew at a 19% CAGR; Loan book grew 12% YoY as at 1H20




- Unrecognised revenue as of 1H20 amounts to S\$599mn; S\$1.93bn of gross development value (GDV) yet to be unlocked for existing projects (5-6 years of revenue)
- Sector 1 of Humen Transit Oriented Development project (GDV: S\$220mn) to commence construction in 2H21, due for handover in 2022/2023.
- Property financing loan book grew at 19% CAGR in the past 5 years, offering recurring income at low to mid-teens returns. We are estimating loan book growth of around 8% for FY20e and FY21e.
- Stunted recovery is expected for the hotel portfolio.

Rating: BUY; TP: S\$1.56



#### Prime US REIT: On course to exceed its NPI targets

Prime US REIT's portfolio consists of 12 Class A freehold office properties that are valued at approximately US\$1.4bn, strategically located in 10 primary markets in the US.




- High income stability supported by minimal expiries; High levels of diversification
  - Occupancy: 93%; WALE: 4.8 years.
  - Largest sector contribution: Communications (3Q20: 16%)
- Well poised to capture organic and inorganic growth opportunities
  - 99.8% of the CRI has built-in rental escalations of 2%
  - Low gearing: 33%; \$92mn available undrawn facility to tap on for future growth opportunities.
- Rent collection at 99% amidst COVID-19.
  - 99% of rents were collected throughout 2Q20 and 3Q20; No rent abatements were provided
  - Rent deferrals = 0.25% of portfolio GRI

Rating: BUY; TP: US\$0.94; Div Yield: 9.2%



#### Lendlease Global Commercial REIT – A cut above the rest

Lendlease Global Commercial REIT's portfolio consists of 313@Somerset and Sky Complex. On 1 October, LREIT acquired an effective 3.75% stake in Jem for S\$45mn.




#### **Investment Merits**

- Highly stable portfolio built for growth
  - Fixed rent component historically contributes more than 95% of LREIT's gross revenue (313: >93%)
  - Both properties have built-in rental escalations: based on CPI for SC and 2.7% for 313.
- Strong organic and inorganic growth outlook
  - Grange Road carpark redevelopment: set to be operational by 1H22 – ROI expected at 10% p.a.
  - Near term: to acquire more stake in Jem. LREIT has a ROFR pipeline of stabilized assets of up to A\$32.4bn.
- Attractive valuations vs peers.
  - FY21e/FY22e dividend yields of 6.1%/6.6% outperform the average forward yields of diversified retail REITs' 5.2%/6.0%.
  - LREIT is also trading at 0.86x P/B, slightly below diversified retail RFITs' 0.90x.

Rating: ACCUMULATE; TP: S\$0.78; Div Yield: 6.1%



#### **Ascott Residence Trust: Potentially faster recovery than peers**




- 74% exposure to countries with large domestic markets
- No-frills, select-service accommodations in a sweet spot
- Increased brand recognition and loyalty programmes
- S\$2.2bn debt headroom for portfolio rebalancing and M&A growth potential
- Rating: **BUY**; TP: **\$\$1.15**;
   FY21e DPU Yield: **5.2%**

Source: The Ascott Limited, PSR



#### Frasers Centrepoint Trust: Boon from increased weekday catchment


#### Projected increase in catchment population



- Suburban malls resilient through cycles due to recurring, necessity-driven spending – 54%
   GRI from essential services
- Increase in catchment size to lift tenant sales
  - i. Permanent hybrid work arrangements
  - ii. 67.6% growth in HDB units in the North
  - iii. Decentralised commercial cluster in the North
- Well-located and managed malls will be prioritised amidst retail consolidation
- Leverage its scale to drive operational synergies through better contract terms from third parties
- Rating: **BUY**; TP: **S\$2.79**; FY21e DPU Yield:
   **5.6%**



### Manulife US REIT - Riding a long WALE





- Defensive portfolio attributes
  - Low expiries due to long WALE of 5.7yrs
  - ✓ Rent escalation of 2% p.a.
  - ✓ Occupancy of 94.3% in 3Q20
- High collection rate of 94% in 3Q20
- US is a mature and remoteworking-adjusted office market – less impact from WFH adoption
- Rating: BUY; TP: U\$\$0.92;
   FY21e DPU Yield: 9.0%

Source: Company, PSR



#### **CapitaLand Limited – Here to stay**





- Earnings stability from diversified portfolio
- High proportion of recurring income
  - Fund mgmt fees from REITs and private funds
  - ii. Mgmt & franchising fees from lodging platform
  - iii. Rental income from investment property
- Unlocking value by recycling funds from mature, non-core assets to new economy assets
- Trading at an attractive 31% discount to RNAV


Rating: **BUY**; TP: **\$\$3.82**;

FY21e DPU Yield: 8.7%



# SGX: Stable and well-hedged

### FY20 Revenue Breakdown



■ Equities ■ FICC ■ DCI

| S\$mn    | FY20 (YoY)   |
|----------|--------------|
| Equities | 760.0 (+14%) |
| FICC     | 171.4 (+23%) |
| DCI      | 121.6 (+19%) |

|        | SDAV (YoY)   | DDAV (YoY) |
|--------|--------------|------------|
| 2Q21   | 1,292 (+21%) | -          |
| Dec-20 | 1,094 (+14%) | -          |
| Nov-20 | 1,726 (+37%) | 0.93 (+8%) |
| Oct-20 | 1,056 (+8%)  | 0.87 (+2%) |
| 1Q21   | 1,242 (+17%) | 0.98 (+1%) |

Source: Bloomberg, Company, PSR

## Sustained market activity through festive season

 4Q SDAV up 21%, DDAV expected to see single-digit growth

# Shook off woes of expiring MSCI equity index futures products

Trading volumes of FTSE substitutes overtook expiring contracts

### Sustainable growth through strategic acquisitions

 BidFX and Scientific Beta acquisition complements current business segments for long-term growth

### Dividend stable and growing


 Quarterly dividend increased to 8.0 cents per quarter, up from 7.5 cents, representing yield of 3.5%

Rating: ACCUMULATE; TP: \$\$9.45



# Hyphens Pharma: Repositioning for growth

# Revenue by Segment (S\$'000)



### Short term profitability hurt by inventory write-offs

\$200k in test kits likely to be written off in 4Q20

### Uptick in healthcare services to benefit sales

 Return of patients to specialist clinics and GPs to boost sales

### Long-term growth narrative intact


- New distribution agreements for Ocean Health® in Sri Lanka and Ceradan® in China
- Award of e-pharmacy licence for WellAway Pharmacy

Rating: ACCUMULATE; TP: S\$0.365

Source: Company, PSR



# iX Biopharma: Cusp of profitability



| Specialty<br>Pharma Drugs | Active<br>Compound | Treatment |
|---------------------------|--------------------|-----------|
| BnoX                      | Buprenophine       | Pain      |
| Wafermine                 | Ketamine           | Pain      |
| Xativa                    | Cannabidiol        | Various   |
| Wafesil                   | Sildenafil         | MED       |
| Silcap                    | Sildenafil         | MED       |



### Shift towards commercialisation to improve profitability

- Revenue up CAGR of 100% over past 2 years
- Six-fold in manufacturing capacity by 2H21 to benefit sales;
   FY21e expected to see 250% increase in sales


# Resumption of travel to facilitate out-licensing deal for Wafermine™

- Ketamine wafer slated for Phase III development trial
- Deal was stalled previously with border closures
- Successful out-licensing will grant upfront and other milestone fee income of S\$8mn in FY21e
- Deal will lift iX Biopharma into profitability in FY21e (FY20: loss of S\$10mn)

Rating: BUY; TP: S\$0.455



# Fortress Minerals Ltd: Rise of an iron ore producer



Iron ore concentrate producer in Malaysia, FY19 was maiden year of commercial production

- Healthy 40% volume growth expected in FY21e.
  - 1HFY21 iron ore production volume surged 57% YoY to 231,007 WMT (wet metric tonnes)
- High profitability due to low-cost structure and proximity to customers.
  - Gross profit margin of 66.7% in FY20
  - Short delivery times expected to ensure captive buyers (domestic steel mills) in Malaysia.
- Considerable exploration upside potential with 5% of concession area (526.2 ha) explored.
   Mining rights will only expire in early 2033.

**Rating: BUY (Under review)** 



# Koufu: New integrated facility to fuel growth



### TOP of integrated facility expected in 1Q2021

- Operations expected to commence by 2Q2021
- Expected to generate new income streams as well as cost efficiencies from food processing

# Potential special dividend from the sale of its existing central kitchen property

 Koufu to potentially realise S\$8mn gain with 1.4 Singapore cents of special dividend to be distributed

### Continued improvement in footfall month-onmonth since end of circuit breaker

- Footfalls at their outlets in Singapore and Macau have been improving month-on-month
- Impairment to be recognised for certain outlets, but will be partially mitigated by rental rebates.

Rating: BUY; TP: S\$0.77



# Keppel Corp: Strategic review of O&M unit and divestments to drive potential re-rating

# Keppel Group's assets

| Assets  | Carrying value S\$bn |
|---|----------------------|
| Landbank/projects under development                       | 7.0                  |
| Assets for monetisation through REITs / trust or for sale | 4.8                  |
| Non-core assets (including Keppel O&M's rigs)             | 3.9                  |
| Funds / investments that can be liquidated over time      | 1.8                  |
| Total carrying value                                      | 17.5                 |

(1) Carrying values of the assets as at 30 June 2020, before taking into account transaction costs, potential tax liabilities, repayment of any asset financing and financing costs

Source: Company, PSR

# Identified S\$17.5bn of assets for monetisation over time

- Divestments of Keppel's assets will likely be speeded up in 2021
- On track for achieving S\$3 5bn in divestments 3 5 years

## Resolution on Keppel O&M to remove key overhang

- Divestment of Keppel O&M to Sembcorp Marine as the most likely outcome of the strategic review
- Resolution on unit to lead to a re-rating of its shares

## Long-term ROE target of 15% reaffirmed

- Keppel's shipyards have resumed operations and many of their activities have resumed
- Greater clarity on target to lead to re-rating

Rating: BUY; TP: S\$6.12



# Conclusion

- 1. Singapore equities in sweet spot valuation, rates, COVID-19
- 2. Equities still the most the rational choice
- 3. Vaccination progress will be key variable to monitor
- 4. STI target (12 months) is 3200



# Quarterly Groundview Magazine

Jan21 Issue

- Why residential is resilient in a pandemic?
- Retail posit COVID-19?
- The threat of e-commerce?
- New way to work for office?
- Opportunities ahead for LHN Group
  - interview

https://www.stocksbnb.com/



# RESEARCH EQUITY TEAM

Head of Research
Paul Chew
paulchewkl@phillip.com.sg

Research Admin
Siti Nursyazwina
syazwina@phillip.com.sg

Consumer | Industrial
Terence Chua
terencechuatl@phillip.com.sg

REITs | Property
Natalie Ong

natalieongpf@phillip.com.sg

Banking & Finance | Healthcare Tay Wee Kuang

taywk@phillip.com.sg

Small-Mid Cap Tan Jie Hui

tanjh@phillip.com.sg

Small-Mid Cap Vivian Ye Qianwei

yeqw@phillip.com.sg

US Equity Yeap Jun Rong

yeapjr@phillip.com.sg

Technical Analyst
Chua Wei Ren

chuawr@phillip.com.sg



# **Ask Questions!**

Research materials (reports & videos) can all be found at:



# StocksBnB.com

Have an opinion or questions on our reports?

Post them in the comment section of the report!

Or visit the 'Community' page.

Send "SUBSCRIBE" to 9782 8025 to receive latest research reports on WhatsApp

82









# Ask us anything

Ask our analysts anything about the market, sectors or any stock counters, here:

## **StocksBnB Community Page**

- 1. Head over to our Community page and <u>ask</u> our analysts anything about the market, sectors or any stock counters.
- 2. <u>Interact</u> with others- share your knowledge and opinions about a topic.



